Krystal Biotech is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 229 staff and has a trailing 12-month revenue of around $95.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $210.69 |
|---|---|
| 52-week range | $93.95 - $214.98 |
| 50-day moving average | $176.74 |
| 200-day moving average | $144.56 |
| Wall St. target price | $189.00 |
| PE ratio | 93.422 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $2.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $210.69 from 2024-07-25
| 1 week (2024-07-19) | 3.45% |
|---|---|
| 1 month (2024-06-26) | 15.64% |
| 3 months (2024-04-26) | 34.30% |
| 6 months (2024-01-26) | 81.58% |
| 1 year (2023-07-26) | 74.25% |
|---|---|
| 2 years (2022-07-26) | 192.26% |
| 3 years (2021-07-26) | 267.18% |
| 5 years (2019-07-26) | 353.39% |
Valuing Krystal Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Krystal Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Krystal Biotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 93x. In other words, Krystal Biotech shares trade at around 93x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Revenue TTM | $95.9 million |
|---|---|
| Operating margin TTM | 12.85% |
| Gross profit TTM | $0 |
| Return on assets TTM | -4.97% |
| Return on equity TTM | 8.87% |
| Profit margin | 59.57% |
| Book value | $28.02 |
| Market Capitalization | $5.8 billion |
TTM: trailing 12 months
We're not expecting Krystal Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $93.95 up to $214.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 0.836. This would suggest that Krystal Biotech's shares are less volatile than average (for this exchange).
Krystal Biotech, Inc. , a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. .
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.